Log In
Print
BCIQ
Print
Print this Print this
 

TevaGrastim, filgrastim (Tbo-filgrastim) (XM02) (formerly Neutroval)

  Manage Alerts
Collapse Summary General Information
Company Teva Pharmaceutical Industries Ltd.
DescriptionShort-acting recombinant form of granulocyte colony-stimulating factor (G-CSF)
Molecular Target Granulocyte colony-stimulating factor (G-CSF) receptor (CSF3R) (CD114)
Mechanism of ActionGranulocyte colony stimulating factor (G-CSF) receptor (CD114) agonist
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationNeutropenia
Indication DetailsTreat chemotherapy-induced neutropenia; Treat severe neutropenia and febrile neutropenia in chemotherapy patients
Regulatory Designation

EU - Biosimilar (Treat chemotherapy-induced neutropenia);
EU - Biosimilar (Treat severe neutropenia and febrile neutropenia in chemotherapy patients)

Partner

Nippon Kayaku Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today